Hookipa Biotech AG

https://www.hookipabiotech.com

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system. HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, selfantigens and next-generation antigens. *

	Start	2011-07-01 established
	Group	Hookipa (Group)
	Successor	Hookipa Biotech GmbH
	Industry	Vaxwave® technology
	Industry 2	HB-101 (Hookipa)
	Person	Aldag, Jörn (Hookipa Biotech 201606– CEO before Uniqure/AMT + Evotec + MAN GHH)
	Person 2	Mummenbrauer, Torsten (ExeVir Bio 202006– CEO before Velvio Gmbh + Hookipa + MorphoSys + GSK Vaccines)

	Region	Wien (Vienna)
	Country	Austria
	Street	2 Helmut-Qualtinger-Gasse Campus Vienna Biocenter
	City	1030 Wien
	Tel	+43-1-890-6360
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2013-10-17)

		* Document for »About Section«: Hookipa Pharma Inc.. (2/26/19). "Press Release: Hookipa Pharma Raises $37.4 Million (€33.2 Million) in Series D Financing". New York, NY & Vienna.

		Record changed: 2023-06-26

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Hookipa (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)